Saint Etienne De Montluc

Researchers are studying pulmonary arterial hypertension PAH, a condition where lung blood vessels become thick and narrow, causing high blood pressure in the lungs and making it hard for the heart to work. PAH can cause difficulty breathing and limit activity. While standard treatments help symptoms, they do not stop the disease from worsening. This research focuses on sotatercept, a targeted therapy aimed at specific proteins involved in PAH, to learn about its long-term safety and tolerability when added to usual PAH treatments. Participants in this long-term follow-up study, who previously took part in certain sotatercept trials, may continue receiving sotatercept by subcutaneous injection every three weeks. Those coming from blinded studies start at 0.3 mgkg with possible increases up to 0.7 mgkg, while those from unblinded studies continue their current dose with possible titration to 0.7 mgkg. The study monitors participants over an extended period to assess continued effects alongside their usual PAH therapy. During the study, participants will have regular assessments including monitoring for adverse events, blood tests for blood components and chemistry, body weight, blood pressure, and ECG readings. Researchers will also evaluate exercise capacity, heart function markers, and risk scores related to PAH. The study aims to follow participants for up to approximately 7 to 8 years to understand long-term safety, treatment tolerability, and health changes while using sotatercept with standard PAH care.

Researchers are evaluating the efficacy of the drug RO7837195 compared to a placebo in adults with moderately to severely active ulcerative colitis UC who have not responded well to conventional or advanced treatments. This Phase IIb study aims to assess the safety, pharmacokinetics, and clinical effects of RO7837195 in this patient group. The study is sponsored by Genentech, Inc. and focuses on treatment outcomes including clinical remission at Week 12. Participants undergo a screening period lasting up to 5 weeks, followed by a 12-week induction phase where some receive RO7837195 and others receive a placebo. After this, all participants enter a 40-week active treatment extension phase receiving RO7837195 regardless of their initial response. This design allows comparison during induction and continued treatment for all in the extension phase. Safety follow-up occurs after the last dose of study treatment. Throughout the trial, participants will be monitored for clinical remission, response, and endoscopic improvements at Week 12, as well as adverse events and drug concentration levels up to Week 65. The study includes regular evaluations such as clinical assessments and laboratory tests to track treatment effects and safety. Total participation can last up to approximately 57 weeks, covering screening, treatment, and follow-up periods.

Researchers are conducting an international clinical program to improve diagnosis, treatment, and understanding of childhood ependymoma in patients under 22 years old. The study aims to harmonize staging and care standards, assess biological markers, and develop treatment recommendations based on age, tumor location, and surgical outcomes. Patients are categorized into three groups based on residual disease and eligibility for radiotherapy to test different therapeutic strategies. The study includes three treatment strata Stratum 1 evaluates the impact of a 16-week chemotherapy regimen with VEC-CDDP after surgery and conformal radiotherapy in patients aged over 12 months to under 22 years with completely removed tumors. Stratum 2 examines the addition of high-dose methotrexate to VEC chemotherapy in patients with residual disease, followed by conformal radiotherapy and possibly an 8 Gy radiotherapy boost for inoperable residual tumors. Stratum 3 studies dose-dense chemotherapy with or without valproate in children under 12 months or those ineligible for radiotherapy. Patients not meeting these criteria enter an observational registry. Participants undergo centralized pathology and imaging reviews to confirm diagnosis and tumor resection status. Assessments include MRI scans, biological marker evaluations, and response to treatments. Researchers monitor progression-free survival, gross total resection rates, treatment response, neuropsychological and neuroendocrine effects, and safety over several years. The study involves scheduled visits, laboratory tests, and follow-up for up to five years to evaluate long-term outcomes.